Conditions: Breast Neoplasm Metastasis
Keywords: Breast Neoplasm Metastasis Receptor,HER-2 Eribulin Furans, ketones Antimitotic agent
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 53
Healthy volunteers: no

Brief summary:
Multicentre, prospective, non-controlled phase II clinical trial to evaluate the efficacy and tolerability of first line single agent Eribulin in patients with HER2-negative metastatic breast carcinoma (MBC) previously exposed to taxanes for early stage.

The primary objective of the study is to determine the median time to progression achieved with Eribulin. Other secondary objectives will be; overall response rate, clinical benefit rate, time to treatment progression, duration of response and toxicity profile.

Detailed description:

Arms:
arm 1: Eribulin Dosage: 1.4 mg/m2 Route of administration: IV bolus Schedule of cycle: D1 and D8 every 21 days

Interventions: intervention 1: Eribulin
Intervention descriptions: intervention 1: None

Protocol document: